Role of immune check point inhibitor rechallenge in metastatic renal cell carcinoma
Immune checkpoint inhibitors (ICIs) have revolutionized treatment of metastatic renal cell carcinoma (mRCC), yet the role and efficacy of ICI rechallenge after disease progression remain uncertain. Response-adaptive escalation in OMNIVORE, HCRN GU16-260, and TITAN-RCC trials showed limited efficacy....
Wedi'i Gadw mewn:
| Prif Awduron: | , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
SAGE Publishing
2025-07-01
|
| Cyfres: | Kidney Cancer |
| Mynediad Ar-lein: | https://doi.org/10.1177/24684562251357795 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|